Jupiter Topco LLC Buys Shares of 47,957 Intellia Therapeutics, Inc. $NTLA

Jupiter Topco LLC bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 47,957 shares of the company’s stock, valued at approximately $812,000.

A number of other institutional investors and hedge funds have also made changes to their positions in NTLA. Comerica Bank lifted its holdings in shares of Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Intellia Therapeutics by 36.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after buying an additional 948 shares during the last quarter. Wealthfront Advisers LLC increased its position in Intellia Therapeutics by 7.6% in the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock worth $185,000 after buying an additional 1,018 shares during the period. Benjamin Edwards Inc. lifted its stake in Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after buying an additional 1,126 shares during the last quarter. Finally, Axxcess Wealth Management LLC lifted its stake in Intellia Therapeutics by 6.1% in the first quarter. Axxcess Wealth Management LLC now owns 22,707 shares of the company’s stock valued at $291,000 after buying an additional 1,308 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NTLA has been the subject of several recent research reports. Wedbush upped their price target on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. Canaccord Genuity Group reiterated a “buy” rating and issued a $49.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, June 16th. New Street Research set a $25.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 15th. Sanford C. Bernstein lifted their price target on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.15.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.50% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $12.74 on Monday. The stock has a market cap of $1.79 billion, a P/E ratio of -3.79 and a beta of 1.82. The firm’s 50-day simple moving average is $12.94 and its 200 day simple moving average is $13.41. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.80). The firm had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. Intellia Therapeutics’s revenue was down 46.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.98) EPS. On average, sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.